Mersana Therapeutics Inc MRSN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/02/24 EDT
3.36quote price arrow down-0.01 (-0.30%)
Volume
799,311
52 week range
0.80 - 9.62
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.36
  • 52 Week High9.62
  • 52 Week High Date06/12/23
  • 52 Week Low0.80
  • 52 Week Low Date07/27/23

Key Stats

  • Market Cap407.578M
  • Shares Out121.30M
  • 10 Day Average Volume1.82M
  • Dividend-
  • Dividend Yield-
  • Beta1.57
  • YTD % Change44.83

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.36
  • 52 Week High9.62
  • 52 Week High Date06/12/23
  • 52 Week Low0.80
  • 52 Week Low Date07/27/23
  • Market Cap407.578M
  • Shares Out121.30M
  • 10 Day Average Volume1.82M
  • Dividend-
  • Dividend Yield-
  • Beta1.57
  • YTD % Change44.83

RATIOS/PROFITABILITY

  • EPS (TTM)-1.50
  • P/E (TTM)-2.24
  • Fwd P/E (NTM)-4.58
  • EBITDA (TTM)-169.44M
  • ROE (TTM)-266.24%
  • Revenue (TTM)36.855M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-465.80%
  • Debt To Equity (MRQ)68.91%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mersana Therapeutics Inc

 

Profile

MORE
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary...
David Mott
Independent Chairman of the Board
Martin Huber M.D.
President, Chief Executive Officer, Director
Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Ashish Mandelia
Chief Accounting Officer, Vice President
Address
840 Memorial Dr
Cambridge, MA
02139-3789
United States

Top Peers

SYMBOLLASTCHG%CHG
CRBU
Caribou Biosciences Inc
3.64-0.05-1.36%
RNAC
Cartesian Therapeutics Inc
24.43+1.79+7.91%
TCRX
TScan Therapeutics Inc
8.65+0.03+0.35%
CCCC
C4 Therapeutics Inc
6.43-0.11-1.68%
ITOS
Iteos Therapeutics Inc
11.49-0.29-2.46%